Smri Case Study

Alzheimer’s disease (AD), a form of degenerative, fatal dementia, is characterized by progressive cognitive decline. While AD is the most common form of dementia, its prevalence has only recently been recognized. When Alois Alzheimer first described the sequence of changes in 1907, physicians believed the disease to be an extremely rare, mid-life condition. It wasn’t until the 1970’s that the same types of changes were shown to occur in both late- and early-onset forms (Cavanaugh et.al. 2008). As such, almost all knowledge of AD has been learned within the past several decades, with new discoveries being reported almost daily. It is now estimated that Alzheimer’s accounts for as many as 60% of all dementias and affects more than 500,000

Subsequently, the full evaluation process that takes place also varies among individuals of different ages and their symptoms experienced (Shimada 47). In the cases of younger onset cognitive impairment with quick progression, an MRI scan and bloodwork are done (Lee et al. 155). From clear MRI scans and blood tests, potential reasonings for Alice’s symptoms, for example brain tumours, can be ruled out. As Alice’s cognitive decline continues, the next step is a PET scan to observe the brain at a molecular level in determining the amyloid levels in the

Alzheimer’s disease (AD) is the most common form of dementia known today. The term “dementia” refers to a variety of conditions that arise from the loss of nerve cell function and/or nerve cell death in the brain, including Alzheimer’s disease, vascular dementia, Parkinson’s disease, Creutzfeldt-Jakob disease and other types of mixed dementia. Although all types of dementia arise from neuronal damage and/or death, each form of dementia is associated with distinct brain abnormalities and symptom patterns. Once a patient has been diagnosed with dementia, a physician must conduct further tests in order to determine the exact form of dementia that is present. Recent research indicates that many individuals,

Alzheimer’s disease (AD) is a progressive and fatal form of dementia, frequently seen in the elderly altering their cognition, thought process and behavior. AD is reported in about half of patients that have a dementia diagnosis; one study states that about 10.3% of the population over 65 years is affected by dementia with an increase to almost 50% over the age of 85. (Beattie, 2002) Alzheimer’s disease is not a normal part of the aging process in humans, but rather found in a group of diseases that affect the brain leading to a decline in mental and physical control. AD when diagnosed has a very slow and gradual course, initially affecting the individual’s short term memory. (Beattie, 2002)

The utilization of biomarkers for Alzheimer 's malady is as yet viewed as trial and is fitting just for use by specialists as of now. The rules call for approving and institutionalizing the utilization of biomarkers before they can be connected in a clinical setting, similar to a specialist 's office. Biomarkers for Alzheimer 's malady did not exist when the first criteria were produced in 1984, and have been considered seriously as of late. (Garrett, M. D., and Valle, R. (2016).

Alzheimer’s disease is the six leading cause of death in America with its major cause still unknown. Scientist understand that even before early onset symptoms appear there are communication errors between the neurons of the brain. As the disease progresses, family members often notice that their loved ones are more forgetful then normal. The disease progressively worsens until one is unable to recognized loved ones, has difficulty speaking, walking, and even swallowing. The brain of one with advanced Alzheimer’s is actually radically different from that have a healthy brain.

Alzheimer’s disease, considered the most common form of dementia, is a degenerative brain disorder which leads to loss of memory and decline of cognitive thinking. Alzheimer’s disease effects over 5 million Americans, a number which is expected to triple in the projected future, and is the sixth leading cause of death in the United States (Dougherty, R.J., et al). Majority of these affected people are sixty-five years of age or older and have what is called late-onset Alzheimer’s, whilst a smaller margin of individuals is younger than sixty-five years of age and are said to have early-onset Alzheimer’s. Alzheimer’s disease presents itself in three main stages, is caused by the degeneration of neurons and by the changes in protein composition in the brain, and despite the lack of definitive, early diagnosis or preventative treatment the disease can to a certain degree be detected and managed.

Alzheimer’s Disease (AD) is characterized by gradual cognitive decline that beings with the inability to create recent memories or thoughts, which then proceeds to effect on all intellectual functions (Mayeux & Stern, 2012). AD affects an estimated 5.5 million people in the United States, and 24 million people worldwide (Mayeux & Stern, 2012). The incidence of Alzheimer’s disease is rising in line with the aging population, therefore; AD is most common in older patients around the ages of 60-85 (Mayeux & Stern, 2012). Alzheimer’s Disease is the sixth most common cause of death ("Latest Alzheimer 's Facts and Figures", 2015). Therefore, in the United States, one individual will develop the disease in every 67 seconds ("Latest Alzheimer 's Facts and Figures", 2015).

There is evidence from older individuals who are deemed “clinically normal” that the process of Alzheimer’s disease starts way before the clinical diagnosis of dementia, thus suggesting a preclinical stage (Sperling et al., 2011). The criteria for the preclinical stage of Alzheimer’s Disease is broken up in three stages. Stage one consists of the presence of A displacement in the brain, stage two is the displacement of A plus neurodegeneration, and stage three is the displacement of A, neurodegeneration, and subdued cognitive deficiencies. The classification for an individual to be grouped into one of these stages is based on the amount of A levels (low levels in the cerebrospinal fluid, or high levels in the brain) and/or the neurodegenerative process (Burnham, et al., 2016).

Alzheimer’s disease is a progressive brain disorder that causes a gradual and irreversible decline of cognitive abilities (Feldman, 2010, p. 325). Informally known as “old timers” disease, it strikes more than half of the elderly community greater than age 85 (Feldman, 2010). In addition to the loss of memory there are also major neurological, functional, and behavioral changes as well. There are a few risk factors including age, family history, and head injuries. There is no definitive way of predicting that a person will get Alzheimer’s, but there are genetic markers and neurological tests that can signify a person’s

Pre-clinical: The pre-clinical stage of Alzheimer’s is a relatively new description for the initial biological changes that are underway before any clinical symptoms are experienced. This stage may begin years, or even decades before symptoms such as memory loss and confusion occur. With the help of magnetic resonance imaging (MRI) or positron emission tomography (PET), and proteins in cerebrospinal fluid (CSF), researchers are able to identify the accumulation of amyloid beta proteins. This occurrence is thought to be connected to structural and functional brain changes similar to those in patients with Alzheimer’s.

Alzheimer’s Disease (AD) is characterized by gradual cognitive decline that beings with the inability to create recent memories or thoughts which then proceeds to influencing all intellectual functions (Mayeux & Stern, 2012) . Alzheimer’s disease leads to premature death and the dependence of someone for daily life functions. (Mayeux & Stern, 2012) If effects an estimated 5.5 million people in the United States and 24 million people worldwide (Mayeux & Stern, 2012). The incidence of Alzheimer’s disease is rising in line with the aging population therefore; Alzheimer’s is most common in older patients around the ages of 60-85 (Mayeux & Stern, 2012).

Alzheimer’s disease (AD) was initially described in 1907 by Bavarian neuropathologist and psychiatrist Alois Alzheimer, and today is defined as a progressive and irreversible decline in cognitive abilities related to memory, behaviors, functionality, orientation, communication, language, abstract thinking and learning (Jacob, 2013). According to the latest figures, AD affects 10% of adults 65 and older and almost 50% of those over the age of 85. There are as many as 4.5 Americans currently living with AD, and the estimated that upwards to 13 million we be inflicted with AD within the next 50 years (Imbimbo, Lombard & Pomara,

Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. To date, it is officially ranked as the sixth leading cause of death in the United States; however, recent estimates indicate that the disorder may actually rank third, just behind heart disease and cancer, as a cause of death for older people. Alzheimer’s, also known as senile dementia, is predominantly the most common cause of dementia among older adults. Dementia is the loss of cognitive functioning and behavioral abilities, particularly thinking, remembering, and reasoning, to such an extent that it interferes with an

First, Alzheimer’s disease is first described by Dr. Alois Alzheimer’s in 1906, and it is named after him. Moreover, in 1968 cognitive measurement scales were discovered, therefor, researchers were allowed to measure